BD Announces 5.1% increase in revenue for the third fiscal quarter

BD Announces 5.1% increase in revenue for the third fiscal quarter -

BD (Becton, Dickinson and Company) (NYSE: BDX), a company global medical technology leading, today announced quarterly revenue of $ 2.157 billion for the third quarter ended June 30, 2014, an increase of 5.1 percent from the period a year earlier, or 4.6 percent on a foreign currency-neutral basis.

"We are pleased with our strong third quarter results, with each of our segments contributing to growth," said Vincent A. Forlenza, Chairman, CEO and President. "Our performance demonstrates that constant our strategy remains strong in this dynamic healthcare environment. "

Third quarter and nine months 2014 financial results of operations
reported earnings per diluted share from continuing operations for the third quarter were $ 1.65 compared to $ 1.47 for the period of the previous year, representing an increase of 12.2 percent. On a foreign currency-neutral basis, earnings per diluted share from continuing operations for the third quarter increased 10.9 percent. The current quarter results include a pretax charge in R & D of $ 9 million or $ 0.03 per diluted share from continuing operations for the programming of asset write-offs and bonds. The results of the prior year included a charge of $ 22 million, or $ 0.07 per share from continuing operations, associated with a settlement antitrust lawsuit. Excluding the impact of these items, adjusted diluted earnings per share from continuing operations were $ 1.68 compared to $ 1.54 for the period of the previous year. This represents an increase of 9.1 percent or 7.8 percent on a currency-neutral basis.

For the nine months ended June 30, 2014, diluted earnings per share from continuing operations were $ 4.47 compared to $ 4.21 in the period last year. This represents growth of 6.2 percent, or 10.0 percent on a currency-neutral basis. Excluding the current quarter charge for the R & D program completion and settlement charge antitrust class action in the district last year, and other factors detailed in the accompanying reconciliation of non-GAAP financial measures to GAAP, adjusted diluted earnings per share from continuing operations for the nine-month period ending June 30, 2014 were $ 4.57 compared to $ 4.28 for the period of the previous year. This represents an increase of 6.8 percent, or 10.5 percent on a currency-neutral basis. Excluding the first quarter differential impact of the excise tax on the medical device, which entered into force in January 2013 under the Affordable Care Act patient protection US, and adjusted diluted earnings per share from continuing were $ 4.62 compared to $ 4.28 for the period of the previous year. This represents growth of 7.9 percent, or 11.7 percent on a currency-neutral basis.

Segment Results
In the medical sector BD, revenues worldwide for the quarter were $ 01000000, representing an increase of 5.3 percent compared to the previous year, an increase of 4.7 percent on a foreign currency-neutral basis. The growth in segment revenues was primarily driven by strong sales in medical surgical systems. For the nine months ended June 30, 2014, BD Medical revenues increased 6.1 percent, or 6.4 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $ 679 million, an increase of 3.7 percent both on a neutral basis and reported abroad compared the previous year. Strong growth in Preanalytical Systems unit were partially offset by continued weakness in health and cancer of women in the US for the nine months ended June 30, 2014, revenues BD Diagnostics rose 2, 0 percent, 3.0 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $ 277 million, representing an increase of 7.7 percent compared to the previous year, an increase of 6, 6 percent on a foreign currency-neutral basis. The segment's growth was driven by solid investment instruments and a favorable comparison with the previous year. For the nine months ended June 30, 2014, BD Biosciences revenues increased 7.1 percent, or 7.6 percent on a currency-neutral basis.

geographical Results
third quarter revenues of US $ 871 million for an increase of 2.8 percent over the period last year. Sales outside the US were $ 12800000, representing an increase of 6.7 percent compared to the previous year, an increase of 6.0 percent on a foreign neutral basis . International revenues reflect the continued strength of the market and sales of emerging security product design.

For the nine months ended June 30, 2014, revenues in the US were $ 2,546,000,000, representing an increase of 1.8 percent compared with the period last year. Sales outside the US were $ 3,698,000,000, representing an increase of 7.1 percent compared to the previous year, or 8.1 percent on a foreign currency-neutral basis.

year 2014 Outlook for
The Company reaffirms its revenue guidance range previously communicated currency neutral 4.5 to 5.0 percent. On a reported basis, the Company expects revenue growth of 4.0 to 4.5 percent. The Company also reaffirmed its previous guidance for diluted earnings per share from continuing operations for the full year is between $ 6.22 and $ 6.25 excluding the impact of the adjustments previously mentioned above. On a reported basis, earnings per share for the full year 2014 expected to be between $ 6.12 and $ 6.15. This represents growth of 7.0 to 7.5 percent over 2013 adjusted diluted earnings per share of $ 5.81. On a foreign currency-neutral basis, diluted adjusted earnings per share growth is expected to be between 10.5 percent to 10.0, 11.0 to 11.5 percent excluding the impact of additional tax on the medical device. The Company expects to complete the acquisition, subject to market conditions, of $ 450 million of its common shares for the year 2014.